Literature DB >> 18516519

Kraepelin and psychotic prodromal conditions.

Joachim Klosterkötter1, Frauke Schultze-Lutter, Stephan Ruhrmann.   

Abstract

When Emil Kraepelin combined the formerly distinct entities of dementia paranoides, catatonia and hebephrenia to form the concept of 'dementia praecox' in 1896, he was well aware that this new disease entity--first coined 'schizophrenia' by Eugen Bleuler in 1908--does not generally only start off with the first psychotic manifestation. Even in his original observations, the characteristic psychotic phenomena developed via transition sequences from rather uncharacteristic prodromal disturbances. Meanwhile an initial prodromal condition was shown for about 75% of first-episode psychosis patients, lasting 5 years on average, possessing pathological significance and leading to psychosocial disruptions. Whereas most symptoms of the initial prodromal condition appear to be rather unspecific and hard to distinguish from other psychiatric conditions especially depressive ones, some syndromes seem to enable an early detection and thus an indicated prevention. These are constituted by attenuated and/or transient psychotic symptoms on the one hand and certain cognitive-perceptive basic symptoms on the other. Whereas the former are thought to delineate an advanced prodromal state, the latter can occur early in course and even at the beginning of the transition sequence to first-rank symptoms. This review will outline the current state of the art of a phase specific early detection and intervention based on these syndromes.

Entities:  

Mesh:

Year:  2008        PMID: 18516519     DOI: 10.1007/s00406-008-2010-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  63 in total

1.  Substance abuse and the onset of schizophrenia.

Authors:  M Hambrecht; H Häfner
Journal:  Biol Psychiatry       Date:  1996-12-01       Impact factor: 13.382

Review 2.  The prevention of schizophrenia.

Authors:  A R Yung; E Killackey; S E Hetrick; A G Parker; F Schultze-Lutter; J Klosterkoetter; R Purcell; P D Mcgorry
Journal:  Int Rev Psychiatry       Date:  2007-12

3.  A survey of delusional ideation in primary-care patients.

Authors:  H Verdoux; S Maurice-Tison; B Gay; J Van Os; R Salamon; M L Bourgeois
Journal:  Psychol Med       Date:  1998-01       Impact factor: 7.723

Review 4.  Bioactive lipids in schizophrenia.

Authors:  Gregor E Berger; Stefan Smesny; G Paul Amminger
Journal:  Int Rev Psychiatry       Date:  2006-04

Review 5.  Neuroleptics and the natural course of schizophrenia.

Authors:  R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

Review 6.  Schizophrenia: the characteristic symptoms.

Authors:  N C Andreasen; M Flaum
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

7.  Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria.

Authors:  L J Phillips; A R Yung; P D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2000-11       Impact factor: 5.744

Review 8.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses.

Authors:  J A Lieberman; B J Kinon; A D Loebel
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

9.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

10.  Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients.

Authors:  Benno G Schimmelmann; Philippe Conus; Sue Cotton; Patrick D McGorry; Martin Lambert
Journal:  Schizophr Res       Date:  2007-07-12       Impact factor: 4.939

View more
  13 in total

1.  Changes in symptom content from a clinical high-risk state to conversion to psychosis.

Authors:  Catherine Marshall; Yun Lu; Kristina Lyngberg; Stephanie Deighton; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel Mathalon; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2017-08-03       Impact factor: 2.732

Review 2.  Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept.

Authors:  Frauke Schultze-Lutter
Journal:  Schizophr Bull       Date:  2009-01       Impact factor: 9.306

3.  Prediction and prevention of psychosis: current progress and future tasks.

Authors:  Stephan Ruhrmann; Frauke Schultze-Lutter; Stefanie J Schmidt; Nathalie Kaiser; Joachim Klosterkötter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-26       Impact factor: 5.270

4.  Shades of vulnerability: latent structures of clinical caseness in prodromal and early phases of schizophrenia.

Authors:  Andrea Raballo; Anna Meneghelli; Angelo Cocchi; Davide Sisti; Marco B L Rocchi; Andrea Alpi; Maria T Cascio; Antonio Preti; Kurt Maurer; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

Review 5.  Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.

Authors:  Daniel C Javitt; Robert Freedman
Journal:  Am J Psychiatry       Date:  2014-11-17       Impact factor: 18.112

6.  Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis.

Authors:  Arsime Demjaha; Lucia Valmaggia; Daniel Stahl; Majella Byrne; Philip McGuire
Journal:  Schizophr Bull       Date:  2010-08-12       Impact factor: 9.306

7.  Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls.

Authors:  Robert A McCutcheon; Kate Merritt; Oliver D Howes
Journal:  World Psychiatry       Date:  2021-10       Impact factor: 79.683

8.  Current status specifiers for patients at clinical high risk for psychosis.

Authors:  Scott W Woods; Barbara C Walsh; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert Heinssen; Diana O Perkins; Larry J Seidman; Sarah I Tarbox; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan
Journal:  Schizophr Res       Date:  2014-07-08       Impact factor: 4.939

9.  Correspondence between psychometric and clinical high risk for psychosis in an undergraduate population.

Authors:  David C Cicero; Elizabeth A Martin; Theresa M Becker; Anna R Docherty; John G Kerns
Journal:  Psychol Assess       Date:  2014-04-07

Review 10.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.